These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 2354440)

  • 1. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
    Hande KR; Kuttesch J; Hamilton M; Satterlee W; Jackson L; Grindey G; Hainsworth JD
    Cancer Res; 1990 Jul; 50(13):3910-4. PubMed ID: 2354440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
    Hainsworth JD; Hande KR; Satterlee WG; Kuttesch J; Johnson DH; Grindey G; Jackson LE; Greco FA
    Cancer Res; 1989 Sep; 49(18):5217-20. PubMed ID: 2766290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.
    Taylor CW; Alberts DS; Ketcham MA; Satterlee WG; Holdsworth MT; Plezia PM; Peng YM; McCloskey TM; Roe DJ; Hamilton M
    J Clin Oncol; 1989 Nov; 7(11):1733-40. PubMed ID: 2809686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
    Brown TD; O'Rourke TJ; Kuhn JG; Craig JB; Havlin K; Burris HA; Cagnola J; Hamilton JM; Grindey GB; Satterlee WG
    Anticancer Drugs; 1994 Apr; 5(2):151-9. PubMed ID: 8049498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human.
    Ehlhardt WJ
    Drug Metab Dispos; 1991; 19(2):370-5. PubMed ID: 1676639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
    Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
    Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
    Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
    Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA; Schmidt CG
    Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
    Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.